secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009791
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx prelim 2025 revenue $672-674M beats guidance; cash $735M; two gene therapy approvals possible in 2026
--------------------------------------------------------------------------------

- Preliminary FY2025 total revenue $672-674M, ~20% YoY, exceeding top end of guidance.
- Crysvita revenue $480-482M (17% YoY, above guidance); Dojolvi $95-97M (9% YoY, at guidance midpoint).
- Cash and investments ~$735M at year-end 2025; full Q4/FY results and 2026 guidance due Feb 2026.
- 2026 catalysts: DTX401 (GSDIa) PDUFA Q3; UX111 (MPS IIIA) BLA resubmission early 2026; GTX-102 (Angelman) Phase 3 data H2 2026.
- UX701 (Wilson disease) pivotal data H1 2026; UX143 (osteogenesis imperfecta) data presented at JPM conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/0001193125-26-009791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/rare-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer